EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review

Guoliang Zhong, Tianqing Yang, Shuqi Lin, Muyi Zhong

Oncology Research · 2026 · 34 (6) · 1-10

DOI: 10.32604/or.2026.076300 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Guoliang Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsPrecision MedicineCyclin-Dependent Kinase 6HumansFemaleReceptors, EstrogenReceptors, ProgesteroneMolecular Targeted TherapyDrug Resistance, NeoplasmAntineoplastic Agents

Stichwörter der Autor:innen

Cyclin-dependent kinases 4 and 6 inhibitorsbreast cancerendocrine therapypersonalized treatment

Substanzen

Cyclin-Dependent Kinase 4Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCyclin-Dependent Kinase 6Receptors, EstrogenCDK4 protein, humanERBB2 protein, humanCDK6 protein, humanReceptors, ProgesteroneAntineoplastic Agents

Autor:innen und Institutionen

  • The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China.
  • Department of Breast Surgery, Dongguan People's Hospital, Dongguan, China.

Zitieren

APA

Zhong, G., Yang, T., Lin, S., & Zhong, M. (2026). Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. Oncology Research, 34(6), 1-10. https://doi.org/10.32604/or.2026.076300

Vancouver

Zhong G, Yang T, Lin S, Zhong M. Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. Oncology Research. 2026;34(6):1-10. doi:10.32604/or.2026.076300

BibTeX
@article{Zhong2026,
  author = {Zhong, Guoliang and Yang, Tianqing and Lin, Shuqi and Zhong, Muyi},
  title = {Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review},
  journal = {Oncology Research},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1--10},
  doi = {10.32604/or.2026.076300}
}
Kostenlos starten →